Efficacy of Carbonlife Amniotic Tissue Product in the Treatment of Chronic Wounds

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 600 participants.

Also called NCT07223892

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Bardia Anvar (from the registry)
Registry
  • NCT NCT07223892
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07223892. Randomized; single masking; primary purpose treatment. Start 2026-01-01 (anticipated); primary completion 2028-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Carbonlife Amniotic Tissue Product in the Treatment of Chronic Wounds
Condition
Chronic Wounds
Condition
Venous Leg Ulcers (VLUs)
Condition
Diabetic Foot Ulcers (DFUs)
Condition
Arterial Ulcers
Condition
Pressure Ulcers
Condition
Burn Wounds
Condition
Trauma Wounds
Condition
Surgical Wounds
Intervention (Biological)
Amniotic Tissue Allograft
Lead sponsor
Bardia Anvar (class: industry)
Collaborator
Carbon Life Sciences (class: industry)

Record details

Record id
cardio:ct-nct07223892
Content hash
8dcb1048383327e0d843d529e4fe787795aa6eac8d30f13e1d3a7db0c25943d8